End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.08 ZAR | +2.04% | +1.61% | +11.05% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.89 for the current period. Therefore, the company is undervalued.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The firm trades with high earnings multiples: 28.97 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.05% | 1.59B | C | ||
-38.61% | 13.83B | B- | ||
-31.33% | 10.96B | B | ||
+13.51% | 6.34B | C | ||
-8.33% | 6.08B | C+ | ||
-30.66% | 6.05B | B | ||
+72.00% | 5.04B | C | ||
-1.61% | 4.67B | D- | ||
-4.84% | 4B | B | ||
-16.14% | 3.28B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DCP Stock
- Ratings Dis-Chem Pharmacies Limited